AAAAAA
Results: 1-25/42
Authors:
DOBSON LS
LORIGAN PC
COLEMAN RE
HANCOCK BW
Citation: Ls. Dobson et al., TOXICITY ASSOCIATED WITH ETOPOSIDE AND DACTINOMYCIN (EA) FOR METHOTREXATE (MTX) RESISTANT, LOW-RISK PERSISTENT TROPHOBLASTIC DISEASE (PTD) AND EA WITH MTX (MEA) FOR HIGH-RISK PTD, Annals of oncology, 9, 1998, pp. 319-319
Authors:
HAMMOND DW
HANCOCK BW
GOYNS MH
Citation: Dw. Hammond et al., CLINICAL IMPLICATIONS OF MOLECULAR AND CYTOGENETIC STUDIES OF NON-HODGKINS-LYMPHOMAS, Cancer treatment reviews, 24(2), 1998, pp. 157-163
Authors:
GOEPEL JR
LORIGAN PC
VANDENBERGHE EA
ALLEN JE
HAMMOND DW
HANCOCK BW
Citation: Jr. Goepel et al., THE CHANGING FACE OF MANTLE CELL LYMPHOMA, British Journal of Cancer, 78, 1998, pp. 6-6
Authors:
DOBSON L
HANCOCK H
EVANS PS
ROBINSON MH
HANCOCK BW
Citation: L. Dobson et al., EXTRANODAL LYMPHOMA - NO CASE FOR COMPLACENCY, British Journal of Cancer, 78, 1998, pp. 7-7
Authors:
GILLESPIE AM
SIDDIQUI N
COLEMAN RE
HANCOCK BW
Citation: Am. Gillespie et al., DOES CENTRAL-NERVOUS-SYSTEM CHEMOPROPHYLAXIS HAVE A ROLE IN THE MANAGEMENT OF GESTATIONAL TROPHOBLASTIC DISEASE, British Journal of Cancer, 78, 1998, pp. 35-35
Authors:
GILLESPIE AM
COLEMAN RE
HANCOCK BW
Citation: Am. Gillespie et al., IS COMPUTED-TOMOGRAPHY NECESSARY TO EVALUATE PULMONARY METASTASES IN PATIENTS WITH PERSISTENT TROPHOBLASTIC DISEASE, British Journal of Cancer, 78, 1998, pp. 54-54
Authors:
HANCOCK BW
AITKEN M
RADSTONE C
HUDSON GV
Citation: Bw. Hancock et al., WHY DONT CANCER-PATIENTS GET ENTERED INTO CLINICAL-TRIALS - EXPERIENCE OF THE SHEFFIELD LYMPHOMA GROUPS COLLABORATION IN BRITISH NATIONAL LYMPHOMA INVESTIGATION STUDIES, BMJ. British medical journal, 314(7073), 1997, pp. 36-37
Authors:
MAINWARING PN
ATKINSON H
CHANG J
MOORE J
HANCOCK BW
GUILLOU PJ
OSKAM R
GORE ME
Citation: Pn. Mainwaring et al., DIFFERENTIAL RESPONSES TO CHEMOIMMUNOTHERAPY IN PATIENTS WITH METASTATIC MALIGNANT-MELANOMA, European journal of cancer, 33(9), 1997, pp. 1388-1392
Authors:
HANCOCK BW
CULLEN MH
HUDSON GV
Citation: Bw. Hancock et al., ALTERNATING CHIVPP PAB1OE IS BETTER THAN PAB1OE ALONE AS INITIAL CHEMOTHERAPY FOR ADVANCED HODGKINS-DISEASE (HD) - FIRST RESULTS OF A BRITISH NATIONAL LYMPHOMA INVESTIGATION (BNLI)/CENTRAL LYMPHOMA GROUP (CLG)STUDY/, European journal of cancer, 33, 1997, pp. 1186-1186
Authors:
ELHELW L
LORIGAN PC
COLEMAN RE
HANCOCK BW
Citation: L. Elhelw et al., THE VEDEX REGIMEN - AN EFFECTIVE AND WELL TOLERATED PALLIATIVE TREATMENT FOR NON-HODGKINS-LYMPHOMA (NHL), European journal of cancer, 33, 1997, pp. 1201-1201
Authors:
FISHER PM
HANCOCK BW
Citation: Pm. Fisher et Bw. Hancock, GESTATIONAL TROPHOBLASTIC DISEASES AND THEIR TREATMENT, Cancer treatment reviews, 23(1), 1997, pp. 1-16
Authors:
CORK MJ
KEOHANE SG
GAWKRODGER DJ
HANCOCK BW
SHERIDAN E
BLEEHEN SS
Citation: Mj. Cork et al., CYTOKINE DERMATOSIS - REACTIVATION OF ECZEMA DURING INTERLEUKIN-2 INFUSION, British journal of dermatology, 136(4), 1997, pp. 644-645
Authors:
GILLESPIE AM
LORIGAN PC
RADSTONE CR
WATERHOUSE JC
COLEMAN RE
HANCOCK BW
Citation: Am. Gillespie et al., PULMONARY-FUNCTION IN PATIENTS WITH TROPHOBLASTIC DISEASE TREATED WITH LOW-DOSE METHOTREXATE, British Journal of Cancer, 76(10), 1997, pp. 1382-1386
INVESTIGATION OF THE RB-1 TUMOR-SUPPRESSOR GENE IN A UNITED-KINGDOM SERIES OF NON-HODGKINS-LYMPHOMAS
Authors:
GRIERSON AJ
HODGKINS MA
HANCOCK BW
GOEPEL JR
ROYDS J
GOYNS MH
Citation: Aj. Grierson et al., INVESTIGATION OF THE RB-1 TUMOR-SUPPRESSOR GENE IN A UNITED-KINGDOM SERIES OF NON-HODGKINS-LYMPHOMAS, Leukemia & lymphoma, 23(3-4), 1996, pp. 353
Authors:
FISHER PM
HANCOCK BW
Citation: Pm. Fisher et Bw. Hancock, HODGKINS-DISEASE IN THE PREGNANT PATIENT, British Journal of Hospital Medicine, 56(10), 1996, pp. 529-532
Authors:
HANCOCK BW
Citation: Bw. Hancock, ADJUVANT INTERFERON IN MELANOMA, British Journal of Cancer, 74, 1996, pp. 5-5
Authors:
LINCH DC
HUDSON BV
HANCOCK BW
HOSKIN PJ
CUNNINGHAM DC
NEWLAND AC
MILLIGAN DW
STEVENSON PA
WOOD JK
MACLENNAN KA
ANDERSON L
GREGORY WM
HUDSON GV
Citation: Dc. Linch et al., A RANDOMIZED COMPARISON OF A 3RD-GENERATION REGIMEN (PACEBOM) WITH A STANDARD REGIMEN (CHOP) IN PATIENTS WITH HISTOLOGICALLY AGGRESSIVE NON-HODGKINS-LYMPHOMA - A BRITISH NATIONAL LYMPHOMA INVESTIGATION REPORT, British Journal of Cancer, 74(2), 1996, pp. 318-322
Authors:
HAMMOND DW
HANCOCK BW
GOYNS MH
Citation: Dw. Hammond et al., ANALYSIS OF 14Q-HODGKINS-LYMPHOMAS BY FLUORESCENCE IN-SITU HYBRIDIZATION( DERIVATIVE CHROMOSOMES IN NON), Leukemia & lymphoma, 20(1-2), 1995, pp. 111
Authors:
FINNEGAN MCM
HAMMOND DW
HANCOCK BW
GOYNS MH
Citation: Mcm. Finnegan et al., ACTIVATION OF MYCN IN A CASE OF NON-HODGKINS-LYMPHOMA, Leukemia & lymphoma, 18(5-6), 1995, pp. 511
Authors:
FINNEGAN MCM
ROYDS J
GOEPEL JR
LORIGAN P
HANCOCK BW
GOYNS MH
Citation: Mcm. Finnegan et al., MDR-1 EXPRESSION IN NON-HODGKINS-LYMPHOMAS IS UNRELATED TO TREATMENT INTENSITY OR RESPONSE TO THERAPY, Leukemia & lymphoma, 18(3-4), 1995, pp. 297
Authors:
WEBB A
MCCARTHY K
CUNNINGHAM D
SLOANE J
LISTER TA
HANCOCK BW
PRENTICE AG
JOHNSON SAN
Citation: A. Webb et al., MULTICENTER RETROSPECTIVE REVIEW OF PRIMARY CUTANEOUS LYMPHOMA EXCLUDING MYCOSIS-FUNGOIDES, European journal of cancer, 31A, 1995, pp. 772-772
Authors:
LORIGAN PC
NEVIN J
RADSTONE C
COLEMAN RE
HANCOCK BW
Citation: Pc. Lorigan et al., ETOPOSIDE AND ACTINOMYCIN-D (EA) FOR METHOTREXATE (MTX) RESISTANT, LOW-RISK, PERSISTENT GESTATIONAL TROPHOBLASTIC DISEASE (GTD) AND EA WITHMTX (MEA) FOR HIGH-RISK GTD, European journal of cancer, 31A, 1995, pp. 1168-1168
Authors:
PICTON SV
BOSEHAIDER B
LENDON M
HANCOCK BW
CAMPBELL RHA
Citation: Sv. Picton et al., SIMULTANEOUS CHORIOCARCINOMA IN MOTHER AND NEWBORN-INFANT, Medical and pediatric oncology, 25(6), 1995, pp. 475-478
Authors:
HANCOCK BW
Citation: Bw. Hancock, NON-HODGKINS-LYMPHOMA - CME LECTURE, Journal of the Royal College of Physicians of London, 29(4), 1995, pp. 340-343
Authors:
FORBAT LN
HANCOCK BW
GERSHLICK AH
Citation: Ln. Forbat et al., METHOTREXATE-INDUCED PERICARDITIS AND PERICARDIAL-EFFUSION - FIRST REPORTED CASE, Postgraduate medical journal, 71(834), 1995, pp. 244-245